ERAP1,2 in Recalcitrant Warts

Serum ERAP1 and ERAP2 Levels in Patients With Recalcitrant Warts

The exact mechanisms underlying the contribution of cellular immunity in the eradication of human papillomavirus (HPV) infections remain obscure. Individuals who have treatment-resistant warts frequently have immune deficiencies. Amino-peptidases (ERAP1, ERAP2) of endoplasmic reticulum are essential for production of antigenic epitopes that attach to the Major Histocompatibility Complex (MHC) class I and activate T-lymphocytes or natural killer (NK) cells. Aim: To assess ERAP1 and ERAP2 serum concentrations in patients with resistant warts.

Inclusion Criteria:

• Patients who had a history of incomplete clearance or recurrence following two or more electrocautery sessions and four or more cryocautery treatments and intralesional bleomycin.

Exclusion Criteria:

• Patients with genital warts
• Patients on systemic steroids or other immunosuppressive treatments
• Immunocompromised individuals
• Patients suffering from chronic systemic diseases
• Pregnant women